Malcolm Taylor

2024

Cryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy

Caldwell, N., Peet, C., Miller, P., Colon, B., Taylor, M., Cocco, M., Dawson, A., Lukac, I., Teixeira, J. E., Robinson, L., Frame, L., Seizova, S., Damerow, S., Tamaki, F., Post, J., Riley, J., Mutter, N., Hanna, J. C., Ferguson, L. & Hu, X. & 13 others, Tinti, M., Forte, B., Norcross, N. R., Campbell, P., Svensen, N., Caldwell, F. C., Postis, V., Read, K. (Lead / Corresponding author), Hudson, C. (Lead / Corresponding author), Gilbert, I. (Lead / Corresponding author), Baragana, B. (Lead / Corresponding author), Pawlowic, M. C. (Lead / Corresponding author) & Jansen, C., 23 Oct 2024, In: Science Translational Medicine. 16, 770, p. 1-12 12 p., eadm8631.

Research output: Contribution to journal › Article › peer-review

Open Access

File

3 Citations (Scopus)

165 Downloads (Pure)

2022

Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target

Wilson, C., Ray, P., Zuccotto, F., Hernandez, J., Aggarwal, A., Mackenzie, C., Caldwell, N., Taylor, M., Huggett, M., Mathieson, M., Murugesan, D., Smith, A., Davis, S., Cocco, M., Parai, M. K., Acharya, A., Tamaki, F., Scullion, P., Epemolu, O. & Riley, J. & 20 others, Stojanovski, L., Lopez-román, E. M., Torres-Gómez, P. A., Toledo, A. M., Guijarro-Lopez, L., Camino, I., Engelhart, C. A., Schnappinger, D., Massoudi, L. M., Lenaerts, A., Robertson, G. T., Walpole, C., Matthews, D., Floyd, D., Sacchettini, J. C., Read, K. D., Encinas, L., Bates, R. H., Green, S. R. (Lead / Corresponding author) & Wyatt, P. G. (Lead / Corresponding author), 13 Jan 2022, In: Journal of Medicinal Chemistry. 65, 1, p. 409-423 15 p.

Research output: Contribution to journal › Article › peer-review

Open Access

File

22 Citations (Scopus)

273 Downloads (Pure)

2021

Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth

Ray, P. C., Huggett, M., Turner, P. A., Taylor, M., Cleghorn, L. A. T., Early, J., Kumar, A., Bonnett, S. A., Flint, L., Joerss, D., Johnson, J., Korkegian, A., Mullen, S., Moure, A. L., Davis, S. H., Murugesan, D., Mathieson, M., Caldwell, N., Engelhart, C. A. & Schnappinger, D. & 17 others, Epemolu, O., Zuccotto, F., Riley, J., Scullion, P., Stojanovski, L., Massoudi, L., Robertson, G. T., Lenaerts, A. J., Freiberg, G., Kempf, D. J., Masquelin, T., Hipskind, P. A., Odingo, J., Read, K. D., Green, S. R. (Lead / Corresponding author), Wyatt, P. G. (Lead / Corresponding author) & Parish, T., 26 Jan 2021, In: ACS Omega. 6, 3, p. 2284-2311 28 p.

Research output: Contribution to journal › Article › peer-review

Open Access

File

25 Citations (Scopus)

221 Downloads (Pure)

2015

Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability

Henderson, C. J., McLaughlin, L. A., Osuna-Cabello, M., Taylor, M., Gilbert, I., McLaren, A. W. & Wolf, C. R. (Lead / Corresponding author), Feb 2015, In: Biochemical Journal. 465, 3, p. 479-488 10 p.

Research output: Contribution to journal › Article › peer-review

Open Access

File

13 Citations (Scopus)

113 Downloads (Pure)

Taylor, Malcolm

Research output

Search results

Cryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy

Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target

Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth

Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability